Pfizer To Appeal India Patent Denial, Cites Bad Investment Environment
This article was originally published in PharmAsia News
Executive Summary
Pfizer said it would appeal the latest Indian Patent Office rejection of its Sutent (sunitinib) cancer drug, whose patent was challenged by Cipla.